People who have had COVID-19 are at increased risk of developing certain inflammatory diseases of the airways, such as asthma, hay fever and chronic sinusitis. However, vaccination against the SARS-CoV-2 virus appears to reduce the risk, according to a comprehensive epidemiological study led by researchers at Karolinska Institutet.

As the nation gears up for the rollout of an updated COVID-19 vaccine, a new study shows the economic benefits of continued broad vaccination in adults. In fact, the country would ultimately save more money that it would spend on vaccinating every person over age 65 with a single dose of an updated mRNA vaccine against coronavirus, the study concludes.

Public health officials had an unprecedented tool for near-instant, widespread communication during the COVID-19 pandemic and mpox epidemic: social media.

Now, one of the first studies of its kind, led by a health policy expert with the Texas A&M University School of Public Health, has found that X (Twitter at the time of the events) brought advantages — as well as disadvantages — in getting the word out.

Rush University Medical Center researchers who for years have been refining the clinical understanding of Long Covid (defined as persistent symptoms for more than three months) today shared findings showing that people experiencing those persistent symptoms also incurred more medical expenses and work-related issues than those who recovered more quickly from Covid-19.  Detailed survey responses since early in the pandemic from more than 3,600 participants in the INSPIRE Covid-19 patient registry also suggests that getting vaccinated against Covid-19 is associated with better work and financial outcome whether people had Long Covid or not

About The Study: In this prospective cohort study of adults with SARS-CoV-2 infection, participants with current self-reported long COVID (defined as developing new, persistent symptoms lasting 3 months or longer after SARS-CoV-2 infection) reported worse work impairment, missed work, and financial distress compared with those who never had long COVID, while vaccination was associated with improved work outcomes and less financial distress even among individuals with long COVID. These data underscore the need for post-pandemic assistance programs, as well as vaccination to decrease societal harms.

The definition of Long COVID varies so widely across published studies that the percentage of people identified as having the condition can differ dramatically, making it harder to treat patients and advance research.

Mucosal Vaccine Delivery Systems: The Future of Immunization (Part 1) is a new release from Bentham Science that delivers a comprehensive exploration of mucosal immunization strategies, offering fresh perspectives and advanced insights into the evolving landscape of vaccine delivery science.

Portland State University researchers have released the final findings in a three-year project examining the impacts of multiple drug policy shifts including Measure 110 which decriminalized drug possession in Oregon. 

The final report finds little evidence that Measure 110 was responsible for rising crime or overdose deaths. Instead, researchers found that trends in crime rates and overdose fatalities were primarily driven by the COVID-19 pandemic and the rise of fentanyl. The report also offers crucial insights for the implementation of the state’s new drug policy (HB 4002), emphasizing that policy change alone isn't enough — successful deflection to treatment depends on robust resources and coordination.

Groundbreaking research led by a Swansea University academic has revealed a synthetic glycosystem — a sugar-coated polymer nanoparticle — that can block Covid-19 from infecting human cells, reducing infection rates by nearly 99%.

Researchers from the Translational Genomics Research Institute (TGen), part of City of Hope, and the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center have identified a potential biomarker for long COVID.

If the findings of their study are confirmed by other research centers, the biomarker could be the first specific and quantifiable indicator for confirming long COVID. Currently, clinicians confer a diagnosis of long COVID based upon a collection of symptoms that patients develop after SARS-CoV-2 infection.